Evorel Sequi contains two patch types. The Evorel 50 patches contain estradiol only (50 mcg per 24 hours). The Evorel Conti patches contain estradiol (50 mcg) and norethisterone acetate (170 mcg per 24 hours). Estradiol is body identical; norethisterone acetate is synthetic. Both patch types use an adhesive matrix and polyester backing, if you have known adhesive sensitivities, mention this to your clinician before starting.

Evorel Sequi is a popular choice among sequential HRT options due to its:

Consistent hormone delivery: As a patch, Evorel Sequi provides steady hormone levels throughout the day and night, reducing the hormonal fluctuations that can occur with oral HRT.

Lower clotting risk: Because it is absorbed through the skin (rather than the digestive system), Evorel Sequi bypasses the liver, which lowers the risk of blood clots and stroke compared to oral oestrogen.

Sequential pattern: Mimics the natural hormonal cycle with oestrogen-only patches for the first 2 weeks, followed by combined patches for the final 2 weeks.

Predictable bleeding: Provides regular withdrawal bleeds, which may be reassuring for some women during the perimenopausal transition.

Twice-weekly application: Simple patch changes every 3-4 days, with no daily medication to remember.

Suitable for perimenopause: Designed for women who are still having periods or have only recently stopped menstruating.

Evorel Sequi is suitable for women who:

• Still have their womb
• Are perimenopausal (still having periods, even if irregular)
• Are in early postmenopause (periods stopped less than a year ago)
• Want a structured HRT that provides regular withdrawal bleeds
• Prefer transdermal (patch) HRT rather than oral medication

If you have not had a period for over a year and are postmenopausal, continuous combined HRT (such as Evorel Conti) is usually more appropriate.

It may not be appropriate if you have:

• Unexplained vaginal bleeding
• A history of certain cancers (particularly breast cancer - discuss with your specialist)
• Current or previous blood clots
• Severe liver disease
• Untreated high blood pressure

Additionally, Evorel Sequi is specifically designed for perimenopausal women or those in early postmenopause. If you have not had a period for over a year, continuous combined HRT (like Evorel Conti) may be more suitable.

Your doctor will assess your medical history to determine if Evorel Sequi is right for you.

Yes, Evorel Sequi is a well-established and effective HRT option for perimenopausal and early postmenopausal women. It provides consistent hormone delivery through the skin in a cyclical pattern, which many women find convenient and well-tolerated. The patch format means you don't need to remember daily medication, and it bypasses the digestive system, which may reduce certain side effects associated with oral HRT.

Evorel Conti is a continuous combined HRT where both oestrogen and progestogen are delivered together throughout the entire cycle. This is designed for postmenopausal women (no periods for over a year) and should not cause monthly bleeding.

Evorel Sequi is a sequential HRT where oestrogen is given for the first 2 weeks, followed by combined oestrogen and progestogen for the final 2 weeks. This is designed for perimenopausal women or those in early postmenopause and typically causes a monthly withdrawal bleed.

The best choice depends on your menopausal status and whether you want to continue having monthly bleeds. Your doctor will help you decide which is right for you.

Evorel Sequi vs Evorel Conti: Evorel Conti delivers oestrogen and progestogen continuously without a break and is designed for fully postmenopausal women who want no monthly bleed. Evorel Sequi has a sequential structure and produces a monthly withdrawal bleed, making it more appropriate for perimenopausal women or those within twelve months of their last period.

Evorel Sequi vs body-identical sequential HRT: Evorel Sequi uses norethisterone acetate, a synthetic progestogen. Women who prefer body-identical progesterone can achieve sequential HRT by combining a transdermal oestrogen with cyclically prescribed micronised progesterone such as Gepretix or Utrogestan. Your clinician can advise whether this approach is more suitable for you.

Evorel Sequi vs oral sequential HRT (e.g. Femoston): Both deliver hormones in a sequential pattern, but Evorel Sequi does so through the skin, bypassing the liver and carrying a lower risk of blood clots and stroke. Oral sequential HRT may suit women who prefer not to use patches or who experience skin sensitivity.

There is no direct link between Evorel Sequi and weight gain. However, some women may notice changes in body composition and metabolism when going through menopause. When starting HRT, some women also experience fluid retention which can feel like weight gain but will eventually settle.

Menopause itself can lead to weight redistribution, particularly around the abdomen, but this can be due to hormonal changes. Some women find that HRT helps them maintain a stable weight. If you have concerns about weight changes while using Evorel Sequi, speak with your doctor to ensure your treatment is right for you.

Bleeding typically occurs during or just after the Evorel Conti patches (weeks 3-4), or at the start of the next cycle when you switch back to Evorel 50 patches. This is called a withdrawal bleed and is caused by the drop in progestogen levels.

The timing and duration of bleeding can vary between women. Some may bleed towards the end of week 4, while others may bleed at the start of the new cycle in week 1. The bleed usually lasts 3-7 days. If you experience unexpected bleeding patterns, heavy bleeding, or no bleeding at all, discuss this with your doctor at your review appointment.

Evorel patches can be cut in half, but this is off-label and should only be done if your doctor or nurse has specifically recommended it for you. Where possible, it is preferable to change to a higher or lower strength patch instead. The manufacturer advises against cutting the patches, as this may affect how well the patch sticks and therefore could lead to less predictable dosing. However, in practice, off-label cutting of patches is sometimes used, particularly during medication shortages.

No, do not make changes to your regimen without speaking to your clinician first. Evorel Sequi is a fixed-dose preparation and the timing of each patch phase is clinically important for womb protection. If your oestrogen dose feels insufficient or the progestogen phase is causing side effects, contact your Voy clinician. Any adjustment would involve switching to an alternative preparation rather than modifying this one.

If your symptoms aren’t improving as expected, it may be a sign that your HRT needs adjusting.

Evorel Sequi patches are available in the UK through NHS prescriptions and private clinics. We are pleased to say Voy has Evorel Sequi in stock. If you are a new patient you will need to book an appointment to access medication.

Yes, Evorel Sequi typically causes a monthly withdrawal bleed that is similar to a period. This is a normal and expected part of sequential HRT. The bleed is called a "withdrawal bleed" rather than a true period because it is caused by the hormonal changes in the HRT cycle, not by ovulation. However, it may feel similar to a natural period.

If you no longer want monthly bleeds, you may be able to switch to continuous combined HRT (such as Evorel Conti) once you are fully postmenopausal (no periods for over a year). Discuss this with your doctor.